Silexion Therapeutics Corp (NASDAQ:SLXN) shares, rose in value on Wednesday, June 18, with the stock price up by 1.77% to the previous day’s close as strong demand from buyers drove the stock to $0.82.
Actively observing the price movement in the last trading, the stock closed the session at $0.81, falling within a range of $0.806 and $0.85. The value of beta (5-year monthly) was 0.116. Referring to stock’s 52-week performance, its high was $122.02, and the low was $0.57. On the whole, SLXN has fluctuated by -12.14% over the past month.
With the market capitalization of Silexion Therapeutics Corp currently standing at about $7.12 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLXN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of SLXN currently trading nearly -12.12% and -10.41% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.68, while the 7-day volatility ratio is showing 2.81% which for the 30-day chart, stands at 4.02%. Furthermore, Silexion Therapeutics Corp (SLXN)’s beta value is 0.11, and its average true range (ATR) is 0.07.
A comparison of Silexion Therapeutics Corp (SLXN) with its peers suggests the former has fared considerably weaker in the market. SLXN showed an intraday change of 1.77% in last session, and over the past year, it shrunk by -99.18%%.
Data on historical trading for Silexion Therapeutics Corp (NASDAQ:SLXN) indicates that the trading volumes over the past 10 days have averaged 0.19 and over the past 3 months, they’ve averaged 1.62 million. According to company’s latest data on outstanding shares, there are 8.69 million shares outstanding.
Nearly 9.05% of Silexion Therapeutics Corp’s shares belong to company insiders and institutional investors own 10.41% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.93 million shares as on 2025-05-30, resulting in a short ratio of 0.83. According to the data, the short interest in Silexion Therapeutics Corp (SLXN) stood at 1036.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 0.78 million. The stock has fallen by -59.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLXN stock heading into the next quarter.
